The anti-IgE/anti-FcεRIα autoantibody network in allergic and autoimmune diseases

G. Marone, G. Spadaro, C. Palumbo, G. Condorelli

Research output: Contribution to journalArticle

Abstract

Basophil granulocytes and tissue mast cells and their mediators play a role in the pathogenesis of several immune and inflammatory disorders. Human basophils and mast cells (FcεRI+ cells) can be activated through immunological interaction with the IgE-FcεRI network. + FcεRI+ cells can be triggered by cross-linking between the Fab portions of IgE and multivalent antigens (direct anaphylaxis). 'Reverse type' anaphylaxis can occur through three distinct mechanisms: antibodies against the Fcε portion of IgE (anti- IgE), antibodies against epitopes of the α chain of FcεRI (anti-FcεRIα) and anti-IgG acting on IgG-IgE complexes bound to FcεRI. Anti-IgE autoantibodies are occasionally present even in normal donors and more frequently in a variety of allergic (chronic urticaria, atopic dermatitis and bronchial asthma) and autoimmune disorders (rheumatoid arthritis, lupus erythematosus and systemic sclerosis). IgG anti-IgE from a small percentage of patients induces the release of mediators from human FcεRI+ cells. Some of the anti-IgE autoantibodies present in allergic patients are non- anaphylactogenic, thus representing a possible protective mechanism preventing the association of IgE with FcεRI. Anti-FcεRIα autoantibodies also occur in a significant percentage of patients of chronic urticaria and probably non-allergic asthma and some autoimmune diseases. Although anti-IgE and anti-FcεRIα autoantibodies, present in a percentage of patients with immune disorders, are relevant to the pathogenesis of these conditions, much remains to be learnt about their immunochemistry, their prevalence and precise role in various inflammatory diseases.

Original languageEnglish
Pages (from-to)17-27
Number of pages11
JournalClinical and Experimental Allergy
Volume29
Issue number1
DOIs
Publication statusPublished - 1999

Fingerprint

Autoantibodies
Immunoglobulin E
Autoimmune Diseases
Mast Cells
Immune System Diseases
Urticaria
Anaphylaxis
Asthma
Immunoglobulin G
Immunochemistry
Basophils
Systemic Scleroderma
Atopic Dermatitis
Granulocytes
Epitopes
Rheumatoid Arthritis
anti-IgE antibodies
Tissue Donors
Antigens
Antibodies

ASJC Scopus subject areas

  • Immunology

Cite this

The anti-IgE/anti-FcεRIα autoantibody network in allergic and autoimmune diseases. / Marone, G.; Spadaro, G.; Palumbo, C.; Condorelli, G.

In: Clinical and Experimental Allergy, Vol. 29, No. 1, 1999, p. 17-27.

Research output: Contribution to journalArticle

@article{8180d4813883406cb9292a0867313908,
title = "The anti-IgE/anti-FcεRIα autoantibody network in allergic and autoimmune diseases",
abstract = "Basophil granulocytes and tissue mast cells and their mediators play a role in the pathogenesis of several immune and inflammatory disorders. Human basophils and mast cells (FcεRI+ cells) can be activated through immunological interaction with the IgE-FcεRI network. + FcεRI+ cells can be triggered by cross-linking between the Fab portions of IgE and multivalent antigens (direct anaphylaxis). 'Reverse type' anaphylaxis can occur through three distinct mechanisms: antibodies against the Fcε portion of IgE (anti- IgE), antibodies against epitopes of the α chain of FcεRI (anti-FcεRIα) and anti-IgG acting on IgG-IgE complexes bound to FcεRI. Anti-IgE autoantibodies are occasionally present even in normal donors and more frequently in a variety of allergic (chronic urticaria, atopic dermatitis and bronchial asthma) and autoimmune disorders (rheumatoid arthritis, lupus erythematosus and systemic sclerosis). IgG anti-IgE from a small percentage of patients induces the release of mediators from human FcεRI+ cells. Some of the anti-IgE autoantibodies present in allergic patients are non- anaphylactogenic, thus representing a possible protective mechanism preventing the association of IgE with FcεRI. Anti-FcεRIα autoantibodies also occur in a significant percentage of patients of chronic urticaria and probably non-allergic asthma and some autoimmune diseases. Although anti-IgE and anti-FcεRIα autoantibodies, present in a percentage of patients with immune disorders, are relevant to the pathogenesis of these conditions, much remains to be learnt about their immunochemistry, their prevalence and precise role in various inflammatory diseases.",
author = "G. Marone and G. Spadaro and C. Palumbo and G. Condorelli",
year = "1999",
doi = "10.1046/j.1365-2222.1999.00441.x",
language = "English",
volume = "29",
pages = "17--27",
journal = "Clinical and Experimental Allergy",
issn = "0954-7894",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The anti-IgE/anti-FcεRIα autoantibody network in allergic and autoimmune diseases

AU - Marone, G.

AU - Spadaro, G.

AU - Palumbo, C.

AU - Condorelli, G.

PY - 1999

Y1 - 1999

N2 - Basophil granulocytes and tissue mast cells and their mediators play a role in the pathogenesis of several immune and inflammatory disorders. Human basophils and mast cells (FcεRI+ cells) can be activated through immunological interaction with the IgE-FcεRI network. + FcεRI+ cells can be triggered by cross-linking between the Fab portions of IgE and multivalent antigens (direct anaphylaxis). 'Reverse type' anaphylaxis can occur through three distinct mechanisms: antibodies against the Fcε portion of IgE (anti- IgE), antibodies against epitopes of the α chain of FcεRI (anti-FcεRIα) and anti-IgG acting on IgG-IgE complexes bound to FcεRI. Anti-IgE autoantibodies are occasionally present even in normal donors and more frequently in a variety of allergic (chronic urticaria, atopic dermatitis and bronchial asthma) and autoimmune disorders (rheumatoid arthritis, lupus erythematosus and systemic sclerosis). IgG anti-IgE from a small percentage of patients induces the release of mediators from human FcεRI+ cells. Some of the anti-IgE autoantibodies present in allergic patients are non- anaphylactogenic, thus representing a possible protective mechanism preventing the association of IgE with FcεRI. Anti-FcεRIα autoantibodies also occur in a significant percentage of patients of chronic urticaria and probably non-allergic asthma and some autoimmune diseases. Although anti-IgE and anti-FcεRIα autoantibodies, present in a percentage of patients with immune disorders, are relevant to the pathogenesis of these conditions, much remains to be learnt about their immunochemistry, their prevalence and precise role in various inflammatory diseases.

AB - Basophil granulocytes and tissue mast cells and their mediators play a role in the pathogenesis of several immune and inflammatory disorders. Human basophils and mast cells (FcεRI+ cells) can be activated through immunological interaction with the IgE-FcεRI network. + FcεRI+ cells can be triggered by cross-linking between the Fab portions of IgE and multivalent antigens (direct anaphylaxis). 'Reverse type' anaphylaxis can occur through three distinct mechanisms: antibodies against the Fcε portion of IgE (anti- IgE), antibodies against epitopes of the α chain of FcεRI (anti-FcεRIα) and anti-IgG acting on IgG-IgE complexes bound to FcεRI. Anti-IgE autoantibodies are occasionally present even in normal donors and more frequently in a variety of allergic (chronic urticaria, atopic dermatitis and bronchial asthma) and autoimmune disorders (rheumatoid arthritis, lupus erythematosus and systemic sclerosis). IgG anti-IgE from a small percentage of patients induces the release of mediators from human FcεRI+ cells. Some of the anti-IgE autoantibodies present in allergic patients are non- anaphylactogenic, thus representing a possible protective mechanism preventing the association of IgE with FcεRI. Anti-FcεRIα autoantibodies also occur in a significant percentage of patients of chronic urticaria and probably non-allergic asthma and some autoimmune diseases. Although anti-IgE and anti-FcεRIα autoantibodies, present in a percentage of patients with immune disorders, are relevant to the pathogenesis of these conditions, much remains to be learnt about their immunochemistry, their prevalence and precise role in various inflammatory diseases.

UR - http://www.scopus.com/inward/record.url?scp=0032901816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032901816&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2222.1999.00441.x

DO - 10.1046/j.1365-2222.1999.00441.x

M3 - Article

C2 - 10051698

AN - SCOPUS:0032901816

VL - 29

SP - 17

EP - 27

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

SN - 0954-7894

IS - 1

ER -